Ask about this productRelated genes to: BUB1B antibody
- Gene:
- BUB1B NIH gene
- Name:
- BUB1 mitotic checkpoint serine/threonine kinase B
- Previous symbol:
- -
- Synonyms:
- BUBR1, MAD3L, Bub1A, SSK1
- Chromosome:
- 15q15.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-25
- Date modifiied:
- 2019-04-23
Related products to: BUB1B antibody
Related articles to: BUB1B antibody
- Environmental and chemical exposures are major yet incompletely characterized drivers of human carcinogenesis. Aflatoxin, a potent food-borne mycotoxin, has been implicated in tumor initiation, proliferation, and immune suppression in intrahepatic cholangiocarcinoma (ICC), but its genomic mechanisms remain poorly defined. - Source: PubMed
Publication date: 2026/03/31
Li FengpingMa YuanyangCheng YanZou Shanshan - Soft tissue sarcomas are rare malignant mesenchymal tumors for which accurate diagnosis, prognostic stratification, and therapeutic decision-making remain challenging. Although histopathology and immunohistochemistry are essential diagnostic tools, they frequently fail to capture the molecular complexity underlying tumor aggressiveness and treatment resistance. In this study, we evaluated the utility of RNA-based next-generation sequencing for the molecular characterization of STS and for elucidating transcriptomic mechanisms associated with aggressive tumor behavior. An observational cohort of 24 patients with histologically confirmed soft tissue sarcomas was analyzed, using adipose and skeletal muscle tissue as controls. RNA was extracted from tumor samples, libraries were prepared with a targeted pan-cancer panel, and sequencing was performed on the Illumina platform, followed by bioinformatic analysis using DRAGEN pipelines and DESeq2. RNA-NGS identified a predominance of single-nucleotide polymorphisms and significant differential gene expression, with overexpression of proliferation-related genes (, , ), extracellular matrix and microenvironment-associated genes (, ), and developmental regulators (, ). Subgroup analysis revealed a distinct transcriptomic profile in leiomyosarcoma, while gene fusion analysis detected clinically relevant alterations. These findings demonstrate that RNA-NGS provides biologically and clinically meaningful insights into the molecular landscape of soft tissue sarcomas and supports its integration into precision medicine-oriented diagnostic workflows. - Source: PubMed
Publication date: 2026/03/16
Serban BogdanCursaru AdrianIordache SergiuCretu BogdanNica MihaiIacobescu GeorgianPopa MihneaRadu EugenCirnu MadalinaCirstoiu Catalin - Breast cancer (BC) is one of the most common malignancies in women globally, characterized by significant genetic and clinical heterogeneity. This complexity emphasises the need for reliable biomarkers and novel therapeutic strategies to improve patient outcomes.To address this, the present study introduces an integrated computational pipeline using multiple datasets to identify robust biomarkers and potential repurposed drugs in BC. From transcriptomic profiles across 12 GEO datasets, 143 differentially expressed genes (DEGs) were identified. Gene Ontology and functional enrichment analyses were performed, followed by the construction of a protein-protein interaction (PPI) network to pinpoint hub genes. These hubs were prioritised using multiple topological centrality measures and validated with independent datasets (cBioPortal, GEPIA, KM plotter) and machine-learning classification using five algorithms: Random Forest, XGBoost, Support vector machine, K-nearest neighbour, and Logistic regression. Machine-learning models achieved test accuracies > 0.90 on TCGA-BRCA data (n = 1203), with K-nearest neighbour (class-weighted: accuracy 0.954) and XGBoost (SMOTE: accuracy 0.931) showing the strongest performance. Prioritised hub genes, TPX2 and BUB1B, were subjected to virtual-screening across five drug databases (DrugBank, DGIdb, OpenTargets, SwissTargetPrediction, and GSCALite), combined with molecular-docking, ADMET profiling, and drug-likeness evaluation, to identify promising repurposed candidates. Vorinostat exhibited the highest binding affinity to TPX2 (-29.32 kcal/mol) and BUB1B (-23.71 kcal/mol), followed by BRD-K90370028 (-18.40 kcal/mol on BUB1B), NSC19630 and Dasatinib (with consistent dual-target binding), CD-437, and four additional prioritised compounds that exhibited favourable interactions. In conclusion, this coherent transcriptomics-to-therapeutics workflow establishes TPX2 and BUB1B as strong prognostic biomarkers in BC, with promising repurposed drugs targeting these mitotic regulators. - Source: PubMed
Publication date: 2026/03/22
Jakkula Bharath KumarPerugu Shyam - Leishmania donovani can cause visceral leishmaniasis, clinically manifested as fever, hepatosplenomegaly, and anemia. If left untreated, it may lead to death owing to complications from other diseases and infections. However, the pathogenesis of L. donovani infection remains unclear. - Source: PubMed
Publication date: 2026/03/13
Li Fei-RanSun QiWang QingQu Ling-LinLi Zhi-HuiYi Zheng-JunYang Bin-Bin - - Source: PubMed
Publication date: 2026/03/09
Ding FadianGuo YikunZhang HanZhong YunZhang DenghanHuang QiangZheng ZhouLiu GuozhongZhang XiangWeng Shangeng